@FierceMedDev: 23andMe digs in as FDA wants test off the market. Story | Follow @FierceMedDev
@MarkHFierce: Please check out our latest issue of FierceDiagnostics, with lots of great industry news. Issue | Follow @MarkHFierce
> Texas cardiovascular stent maker Palmaz Scientific is close to completing a $30 million funding round. Story
> Echo Therapeutics ($ECTE) said it is on track for a 2013 fourth-quarter CE mark submission for its Symphony wireless continuous glucose monitoring system, following positive results from a multi-center trial. Item
> California's CLR Medicals is recalling its Viscocel and Viscocel Plus ophthalmic devices after the FDA warned the company for marketing them without approval. More
> Diagnostics outfit Invitae intends to defend itself against a lawsuit from Myriad Genetics ($MYGN) over BRCA and MUTYH genetic tests. More
> Myco Medical expects a big revenue boost now that it will supply safety scalpels to medical device supplier novation. Story
Biotech News
@FierceBiotech: What would a Teva buyout mean for its R&D operation? Story | Follow @FierceBiotech
@JohnCFierce: GlaxoSmithKline dispatching R&D teams to new satellites in Cambridge, San Diego. Story | Follow @JohnCFierce
@DamianFierce: Sorin's expecting as much as 10% annual growth by 2018. Story | Follow @DamianFierce
@EmilyMFierce: Malaria cases soar in former rebel stronghold of Rutshuru, DRC. More | Follow @EmilyMFierce
> Korean CRO grabs failed cancer vaccine in $150M-max Jennerex buyout. Story
> Theraclone reels as feds deny funding for flu antibody. News
> Galapagos reaps $46M payday as GSK preps PhII study. Item
Pharma News
@FiercePharma: Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth. Yesterday's story | Follow @FiercePharma
@EricPFierce: Finally, something that Teva can crow about. Treanda gets orphan status, extending its exclusivity. News | Follow @EricPFierce
@CarlyHFierce: Our annual Top Women in Biotech report is live! Special report | Follow @CarlyHFierce
> FDA bans second Wockhardt plant. News
> Adcock Ingram pleads merger essential for survival. Story
> Administration lauds Medicare drug discounts and wants more, more, more. Article
Drug Delivery News
> Study: Natural nanomaterials could support biodegradable drug delivery. Story
> Alnylam pockets $7M from Genzyme as RNAi program hums along. Article
> Aptar Pharma readies auto-injectable drug delivery tech. Report
> Focal Therapeutics' 3-D tissue marker for targeted cancer therapy reaches milestone. Story
> Arrowhead submits PhIIa application for hep B RNAi candidate. Article
> Supramolecular gel scaffold may support bone drug delivery. Item
Diagnostics News
> Veracyte boosts Dx revenue as CEO Anderson celebrates successful IPO. Story
> Canadian team relies on synchrotron to develop better prostate cancer Dx. Article
> In 23andMe's tussle with the FDA, 'diagnostic' is a contentious word. Story
> Oxford Immunotec, a TB Dx developer, performs well in its Nasdaq debut. Report
> Myriad ups companion Dx focus with BioMarin cancer drug collaboration. News
> BioMérieux team touts development of quicker sepsis Dx approach. Item
Biomarkers News
> Blood biomarker points to post-concussion cognitive problems. Report
> Regulus snags milestone in MS biomarker deal with Biogen. News
> Protein C4d linked to higher mortality rates in lung cancer patients. Story
> Women who test negative for BRCA mutation may still have higher breast cancer risk. Article
> Chemical fingerprint points to a likely biomarker for 'fast' form of Parkinson's. More
> Gentris opens biomarker shop in Shanghai. Item
Vaccines News
> FDA approves GSK's adjuvanted bird flu vaccine for stockpile. Report
> Novartis struggling to find vaccine acquisition targets for $5B war chest. Article
> Ranbaxy reportedly ready to sell vaccine unit. More
> Sanofi hunting for bolt-on vaccine deals. Story
> Value of Pentagon-backed vaccine plant questioned. News
> GAVI adds support for inactivated polio vaccine. Item